The Truth About Nicotine and Vaping: INNCO's Perspective

Dec.01.2022
The Truth About Nicotine and Vaping: INNCO's Perspective
Misinformation hinders progress on ending smoking. Nicotine is not the problem, it's the smoke. Safe alternatives for smokers exist.

For many years, nicotine has been demonized by anti-smoking "experts" to discourage smoking. INNCO argues that while quitting smoking should be a shared goal, it is unethical to distort the truth in order to achieve it.


To make matters worse, this practice continues, effectively sentencing smokers to an unnecessary death without providing them an escape route.


Nicotine itself does not cause cancer, cardiovascular or pulmonary diseases. The harm comes from the smoke produced by burning cigarettes. Therefore, it is necessary to promote the use of safer nicotine substitutes to replace toxic tobacco products and save the lives of smokers. Failing to do so is tantamount to involuntary manslaughter.


Several months ago, Dr. Sara Kayat appeared on ITV's "This Morning" show alongside hosts Alison Hammond and Dermot O'Leary to issue unverified warnings about nicotine electronic cigarettes (commonly known as "e-cigarettes"). Dr. Kayat stated, "There are many other issues starting to surface...the most concerning is lung damage. There's a condition called popcorn lung. This is an inflammatory lung disease that may occur from using e-cigarettes.


The International Network of Nicotine Consumer Organizations (INNCO) stated that there is no evidence to support the claim made and presenting such misinformation can have an adverse effect on efforts to quit smoking. When healthcare professionals make assumptions based on incomplete investigations and present them as facts, it creates fear and unnecessary concern, ultimately preventing people from making informed decisions about their health and well-being. Preventing smokers from switching to safer alternatives such as nicotine e-cigarettes is akin to causing a public health tragedy.


2FIRSTS will continue to cover this topic and provide updates on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Arkansas to Ban Non-FDA Approved Vapes Starting September 1
Arkansas to Ban Non-FDA Approved Vapes Starting September 1
Arkansas’ new law, Act 590, will restrict the sale of certain vape products across the state. The law requires retailers to sell only products that are approved or under review by the U.S. Food and Drug Administration (FDA), and bans packaging or designs that appeal to minors. Violations could result in product seizures, fines, or even license revocation.
Aug.27 by 2FIRSTS.ai
  Special Report|UK’s Disposable Vape Ban: Compliance Products on the Rise, Yet Loopholes and Weak Enforcement Raise Concerns
Special Report|UK’s Disposable Vape Ban: Compliance Products on the Rise, Yet Loopholes and Weak Enforcement Raise Concerns
On 1 June 2025, the UK officially implemented a ban on disposable e-cigarettes. However, within just two months, the market was flooded with a large number of "replica reusable e-cigarettes," and many consumers continued to use them in a "disposable" manner. After the ban was implemented, did the UK e-cigarette market undergo a compliant restructuring, or did it descend into another form of chaos?
Aug.25
Gold Standard for Natural Nicotine Regulation? — Heno Bio Explains What Nicotine Companies Can Learn from JUUL's PMTA
Gold Standard for Natural Nicotine Regulation? — Heno Bio Explains What Nicotine Companies Can Learn from JUUL's PMTA
In July 2025, JUUL received FDA PMTA approval, marking a new era of higher scientific standards in the vaping industry. Using high-purity natural nicotine and submitting detailed toxicology and stability data, JUUL set a new benchmark for regulatory compliance. 2Firsts invited leading natural nicotine manufacturer Heno Bio to analyze JUUL’s success and highlight the importance of science-based evaluation and regulatory foundations.
Aug.04
Exclusive 2Firsts Contribution | Dr. Ziauddin Islam: Smoke-Free Pakistan — Dream or Reality?
Exclusive 2Firsts Contribution | Dr. Ziauddin Islam: Smoke-Free Pakistan — Dream or Reality?
This article, contributed by Dr. Ziauddin Islam, public health professional and former Focal Person of Pakistan to the WHO FCTC, reflects on Sweden’s achievement as the first “smoke free” nation. He argues Pakistan can learn from Sweden’s strict policies and harm reduction strategy, urging stronger enforcement, public awareness, and adoption of reduced-risk products to move toward a smoke free future.
Sep.01
2Firsts to Host Special Session at InterTabac on September 19
2Firsts to Host Special Session at InterTabac on September 19
2Firsts will host a special session at the InterTabac exhibition in Dortmund on September 19, 2025, under the theme “From Change to Opportunity.” As an official media partner, 2Firsts will highlight technology, supply chain, market, and capital opportunities while fostering global dialogue.
Sep.15
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
The EU’s consultation on the Cardiovascular Health Plan, though not mentioning nicotine, has sparked debate over novel tobacco regulation. Advocates urge evidence-based recognition of harm reduction products, while opponents call for tighter rules. The plan may influence TPD III, drawing close scrutiny from both industry and health groups.
Sep.01